Philippe JEAN-PIERRE

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/09/2025
• Auteurs : Lucie CrosAntoine GusdorfPhilippe SaloméSergiy StepkinPhilippe ZarkaPedro SalasAlan LohPierre LesaffreJonathan FreundlichMarta AlvesFrancois BoulangerAndrea BraccoStéphane CorbelMaryvonne GerinJavier R. GoicoecheaIsabelle GrenierJean-Mathias GriessmeierMartin HoudeOleksandr KonovalenkoAntoine MarchalAlexandre MarcowithFlorent MertensFrédérique MotteMichel TaggerAlexander TielensG TheureauPeter TokarskyOleg UlyanovVyacheslav Zakharenko
• Organismes : Astrophysique Astrophysique Laboratoire d’étude de l’Univers et des phénomènes eXtrèmes Laboratoire d’étude de l’Univers et des phénomènes eXtrèmes Laboratoire de physique de l'ENS - ENS Paris Laboratoire d’Instrumentation et de Recherche en Astrophysique National Radio Astronomy Observatory [Green Bank] Laboratoire d’Instrumentation et de Recherche en Astrophysique Astrophysique Observatoire astronomique de Strasbourg Astrophysique Astrophysique Astrophysique Interprétation Modélisation Laboratoire d’étude de l’Univers et des phénomènes eXtrèmes Instituto de Física Fundamental [Madrid] Astrophysique Interprétation Modélisation Laboratoire de Physique et Chimie de l'Environnement et de l'Espace Department of Physics and Astronomy [London, ON] Institute of Radio Astronomy of NAS of Ukraine Research School of Astronomy and Astrophysics [Canberra] Laboratoire Univers et Particules de Montpellier Laboratoire d’étude de l’Univers et des phénomènes eXtrèmes Institut de Planétologie et d'Astrophysique de Grenoble Laboratoire de Physique et Chimie de l'Environnement et de l'Espace Leiden Observatory [Leiden] Laboratoire de Physique et Chimie de l'Environnement et de l'Espace Institute of Radio Astronomy of NAS of Ukraine Institute of Radio Astronomy of NAS of Ukraine Institute of Radio Astronomy of NAS of Ukraine Laboratoire de Physique et Chimie de l'Environnement et de l'Espace
• Publié dans Astronomy & Astrophysics - A&A le 28/10/2020

---

Résumé : Context. Carbon radio recombination lines (CRRLs) at decametre wavelengths trace the diffuse phase of the interstellar medium (ISM) of the Galaxy. Observations of these lines allow for physical parameters of this phase to be measured.Aims. We observed CRRLs with the recently commissioned New Extension in Nançay Upgrading LOFAR (NenuFAR) telescope towards two of the brightest sources at low-frequency (10–85 MHz): Cassiopeia A and Cygnus A (hereafter, Cas A and Cyg A, respectively). We then measured the density, ne, and temperature, Te, of the electrons in line-of-sight clouds.Methods. We used NenuFAR’s beam-forming mode and integrated several tens of hours on each source. The nominal spectral resolution was 95.4 Hz. We developed a reduction pipeline primarily aimed at removing the radio frequency interference (RFI) contamination and correcting the baselines. We then performed a first fitting of the spectral lines observed in absorption associated with the line-of-sight clouds.Results. Cas A is the brightest source in the sky at low frequencies and represents an appropriate test bench for this new telescope. On this source, we detected 398 Cα lines between the principal quantum numbers n = 426 and n = 826. Cyg A is also a bright source, however, the Cα lines were observed to be fainter. We stacked the signal by groups of a few tens of lines to improve the quality of our fitting process. For both sources, we reached a significantly higher signal-to-noise ratio (S/N) and spectral resolution than the most recent detections by the LOw Frequency ARray (LOFAR). The variation of the spectral line widths with the electronic quantum number provides constraints on the physical properties of the clouds: Te, ne, and the temperature, T0, of the radiation field, the mean turbulent velocity, νt, and the typical size of the cloud.Conclusions. Our final constraints differ from those inferred from LOFAR results, with ∼50% lower Te, ∼35% lower ne, and from 10 to 80% higher νt, on average. The NenuFAR observations sample a larger space volume than LOFAR’s towards the same sources due to the differences in instrumental beam sizes. These discrepancies highlight the sensitivity of low-frequency CRRLs as probes of the diffuse ISM, paving the way towards large area surveys of CRRLs in our Galaxy.

---

Fichiers liés : aa55085-25.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/09/2025
• Auteurs : Clément DesjardinsStéphan GrimaldiSheng LuoLuowen YuChristopher GoetzGlenn StebbinsPablo Martinez-MartinMonica KurtisTiago MestreAlvaro Sanchez-FerroMichelle H.S. TosinRoberta BalestrinoChi‐ying LinCarmen Gasca-SalasTatiana WitjasOlivier ColinDavid MalteteLuc DefebvreCaroline GiordanaMahmoud CharifClaire ThiriezChloé LaurencinFazia Mélissa TirGwendoline DupontPhilippe RemyChristine TranchantSophie DrapierAlexandra SamierIsabelle BenatruSara SambinJean-Christophe CorvolFatma KhelifiMargherita FabbriOlivier J. Rascol
• Organismes : Hôpital Avicenne [AP-HP] Centre d'Exploration Métabolique par Résonance Magnétique [Hôpital de la Timone - APHM] Centre de résonance magnétique biologique et médicale Beijing Key Lab of Digital Plant Duke University [Durham] Institute of Health Carlos III Centro de Investigacion Biomédica en Red sobre Enfermedades Neurodegenerativas Hospital Ruber Internacional [Madrid, Spain] Institut de Neurosciences de la Timone CHU Rouen Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 Centre Hospitalier Universitaire de Nice Centre Hospitalier Régional Universitaire [Montpellier] Institut des Neurosciences de Montpellier Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL] Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Pathophysiologie de la maladie de Parkinson et des troubles associés CHU Amiens-Picardie Laboratoire de Neurosciences Fonctionnelles et Pathologies - UR UPJV 4559 Institut Mondor de Recherche Biomédicale Centre d'Investigation Clinique [Rennes] Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Institut du Cerveau = Paris Brain Institute Institut du Cerveau = Paris Brain Institute Centre d’Excellence en Maladies Neurodégénératives Centre d’Excellence en Maladies Neurodégénératives
• Publié dans Movement Disorders Clinical Practice le 01/02/2019

---

Fichiers liés : Movement Disord Clin Pract - 2025 - Desjardins - Validation of the French Translation of the Movement Disorder Society.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/09/2025
• Auteurs : Liem Binh Luong NguyenLyvia MagloireAlexis FrançoisDavid BillardFrank PriouJennifer ArrondeauClaude LinassierInes Ben GhezalaMarine Gross-GoupilJulie CharlesNadine DohollouPhilippe VanhemsClaire CracowskiAnne Marie LeroiFabrice LainéFlorence GaltierKarine BarthelemyStéphane PrietMariam GharibMathieu ChalouniAude BarquinPaul LoubetXavier de LamballerieOdile LaunayLinda WittkopJean-Yves BlayJean-Philippe Spano
• Organismes : CIC Cochin Pasteur F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC) Université de Bordeaux Université de Bordeaux Hôpital Foch [Suresnes] Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris] Cancer Research and Personalized Medicine - CARPEM [Paris] Centre Hospitalier Régional Universitaire de Tours Centre d'Investigation Clinique 1432 (Dijon) - Epidemiologie Clinique/Essais Cliniques Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand Hôpital Saint-André [Bordeaux] F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC) CHU de Grenoble-Alpes - Centre Hospitalier Universitaire CHU Grenoble Institute for Advanced Biosciences / Institut pour l'Avancée des Biosciences (Grenoble) Polyclinique Bordeaux Nord Aquitaine Hôpital Edouard Herriot [CHU - HCL] Université Claude Bernard Lyon 1 Centre d'Investigation Clinique [Grenoble] Centre d'Investigation Clinique [CHU Rouen] Service de Physiologie Digestive, Urinaire, Respiratoire et de l'Exercice [CHU Rouen] Centre d'Investigation Clinique [Rennes] Hôpital Sud [CHU Rennes] CIC Montpellier Hôpital Saint Eloi [CHU Montpellier] Unité des Virus Emergents Unité des Virus Emergents ANRS - Maladies infectieuses émergentes Université de Bordeaux Université de Bordeaux Centre Hospitalier Universitaire de Nîmes Virulence Bactérienne et Infections Chroniques F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC) Unité des Virus Emergents F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC) CIC Cochin Pasteur Centre Hospitalier Universitaire de Bordeaux Institut Bergonié [Bordeaux] CIC Bordeaux Statistics In System biology and Translational Medicine Centre Léon Bérard [Lyon] Université Claude Bernard Lyon 1 Environnement, Mobilité et Santé [iPLesp] CHU Pitié-Salpêtrière [AP-HP]
• Publié dans Vaccine le 26/10/2020

---

Résumé : Background: Patients with cancer, whose immune responses to vaccines are commonly weaker than those of the general population, are recommended a booster dose after two initial doses of Covid-19 vaccine. Our objective was to compare the humoral immunogenicity of Covid-19 vaccines in patients with cancer compared to healthy adults (control group) after primary vaccine series and after a booster dose. Methods: We included participants aged ≤75 and vaccinated with two doses in the primary vaccine series and a booster, from the French national prospective Covid-19 vaccine cohort study (ANRS0001S COV-POPART) and excluded those with SARS-CoV-2 infection. Percentage of responders, geometric mean titers (GMT) of anti-SARS-CoV-2 IgG antibodies (ELISA) and specific neutralizing antibodies against original strain, Delta and Omicron variants of concern, were estimated one month after the primary vaccine series, then one month and six months after a booster dose. Results: We included 183 patients with cancer and 1173 controls. The most frequent cancers were breast (37.2 %) and lung cancer (17.5 %). Patients with cancer were older and had lower anti-Spike IgG levels after the primary vaccine series (GMT = 132.4 vs 332.7 BAU/mL, P < 0.0001), but they developed similar response at one month (GMT = 2146.1 vs 1841.3 BAU/mL], P = 0.16) and six months after booster (602.0 vs 574.4 BAU/mL, P = 0.80). Neutralizing antibodies levels confirmed these results. Conclusion: Patients with cancer have comparable response rates to controls one month and six months after a booster dose. Our results support the benefit of a booster dose in patients with cancer.

---

Fichiers liés : 1-s2.0-S0264410X25009302-main.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/09/2025
• Auteurs : Claire V HoffmannYannick Le MeurMarie-Christine MoalAnne Grall-JézéquelNathan Le NanNicolas PaponGilles NevezSolène Le GalAnne TotetHakim MazouzJean-Philippe BoucharaVirginie BessonEmeline SchererDidier DuclouxKonrad MühlethalerPierre L BonnetJulie BonhommeThierry LobbedezValérie ChateletCéline NourrissonCyril GarrousteFrançoise BotterelMarie MatignonFrederic DalleClaire TinelDanièle Maubonjohan nobleBoualem SendidJordan LeroyFrançois ProvotMarie-Fleur DurieuxClément DanthuJean MenottiFrançois BaillyChristophe RavelMoglie Le QuintrecAnne DebourgogneMarc LadriereFlorent MorioMagali GiralLilia HasseineLaetitia AlbanoNicolas ArgyRichard DorentArnaud FekkarValérie PourcherEstelle CateauAntoine ThierryAntoine HugueninAlain WynckelFlorence Robert-GangneuxElsa VabretDamien CostaBertrand DominiquePierre FloriEmmanuelle TavernierJulie BrunetLaura BraunXavier IriartArnaud del BelloGuillaume DesoubeauxMatthias BuchlerNatalja KulaginaVincent Courdavault
• Organismes : Hôpital de la Cavale Blanche - CHRU Brest Centre Hospitalier Régional Universitaire de Brest Infections Respiratoires Fongiques CHRU Brest - Service de Nephrologie Lymphocytes B, Autoimmunité et Immunothérapies CHRU - Service de néphrologie, dialyse et transplantation rénale CHRU Brest - Service de Nephrologie Université de Brest Infections Respiratoires Fongiques SFR UA 4208 Interactions Cellulaires et Applications Thérapeutiques SFR UA 4208 Interactions Cellulaires et Applications Thérapeutiques Infections Respiratoires Fongiques Infections Respiratoires Fongiques Laboratoire de Parasitologie et Mycologiede [CHRU Brest] Université de Brest Université de Brest Infections Respiratoires Fongiques Laboratoire de Parasitologie et Mycologiede [CHRU Brest] Agents infectieux, résistance et chimiothérapie - UR UPJV 4294 CHU Amiens-Picardie Unité de Transplantation Rénale et Pancréatique [CHU Sud, Amiens] SFR UA 4208 Interactions Cellulaires et Applications Thérapeutiques Infections Respiratoires Fongiques Centre Hospitalier Universitaire d'Angers Centre Hospitalier Universitaire d'Angers Laboratoire Chrono-environnement (UMR 6249) Service de parasitologie et mycologie [CHRU de Besançon] Centre Hospitalier Régional Universitaire de Besançon Service de Néphrologie [CHRU Besançon] Université de Bordeaux CHU Caen Normandie – Centre Hospitalier Universitaire de Caen Normandie CHU Caen Normandie – Centre Hospitalier Universitaire de Caen Normandie Centre Universitaire des Maladies Rénales [CHU Caen] Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias Service Néphrologie, Hémodialyses [CHU Clermont-Ferrand] Dynamic Microbiology - EA 7380 Hôpital Henri Mondor Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand Institut Necker Enfants-Malades Service Néphrologie et transplantation rénale Adultes [CHU Necker] CHU de Grenoble-Alpes - Centre Hospitalier Universitaire CHU Grenoble CHU de Grenoble-Alpes - Centre Hospitalier Universitaire CHU Grenoble Unité de Glycobiologie Structurale et Fonctionnelle - UMR 8576 Centre Hospitalier Régional Universitaire [CHU Lille] Service de Parasitologie-Mycologie [CHRU LIlle] Unité de Glycobiologie Structurale et Fonctionnelle - UMR 8576 Centre Hospitalier Régional Universitaire [CHU Lille] Université de Limoges Service de Néphrologie, Dialyse, Transplantations [CHU Limoges] Institut des Agents Infectieux [Lyon] CHU Lyon Centre Hospitalier Régional Universitaire [Montpellier] Maladies infectieuses et vecteurs : écologie, génétique, évolution et contrôle Department of Nephrology, Dialysis and Transplantation, Montpellier University Hospital Centre Hospitalier Régional Universitaire de Nancy Stress, Immunité, Pathogènes Université Claude Bernard Lyon 1 Hospices Civils de Lyon Cibles et Médicaments des Infections et de l'Immunité - UR 1155 Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre de Recherche en Transplantation et Immunologie - Center for Research in Transplantation and Translational Immunology Team 4 : Deciphering organ immune regulation in inflammation and transplantation (DORI-t) Institut de Transplantation et de Recherche en Transplantation [CHU Nantes] CHU Nice [Cimiez] Département de Néphrologie - Hôpital Pasteur [Nice] AP-HP - Hôpital Bichat - Claude Bernard [Paris] Agence de la biomédecine [Saint-Denis la Plaine] CHU Pitié-Salpêtrière [AP-HP] Institut Pierre Louis d'Epidémiologie et de Santé Publique CHU Pitié-Salpêtrière [AP-HP] Centre hospitalier universitaire de Poitiers = Poitiers University Hospital Microorganismes, Hôtes, Environnements [Équipe du laboratoire EBI Poitiers] Ischémie reperfusion, métabolisme et inflammation stérile en transplantation [U 1313] Université de Poitiers = University of Poitiers Centre hospitalier universitaire de Poitiers = Poitiers University Hospital Service de néphrologie - hémodialyse et transplantation rénale [CHU Poitiers] Epidémiosurveillance de protozooses à transmission alimentaire et vectorielle Hôpital universitaire Robert Debré [Reims] Hôpital universitaire Robert Debré [Reims] Institut de recherche en santé, environnement et travail Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Université de Rennes École des Hautes Études en Santé Publique Arènes: politique, santé publique, environnement, médias Recherche sur les services et le management en santé Université de Rouen Normandie Département de Microbiologie [CHU Rouen] UNIROUEN - UFR Santé Service de Néphrologie [Rouen] Service des Agents Infectieux et Hygiène [CHU Saint-Etienne] Institut de Cancérologie de la Loire Lucien Neuwirth Laboratoire de Parasitologie et de Mycologie Médicale [Strasbourg] Dynamique des interactions Hôte pathogène service de Néphrologie et Transplantation Rénale [CHU Strasbourg] Centre Hospitalier Universitaire de Bordeaux Institut Toulousain des Maladies Infectieuses et Inflammatoires Centre Hospitalier Universitaire de Toulouse Centre d’Etude des Pathologies Respiratoires [Tours] Service de néphrologie et immunologie clinique [CHRU Tours] Université de Tours Biomolécules et Biotechnologies Végétales Biomolécules et Biotechnologies Végétales
• Publié dans The Lancet Microbe le 11/12/2020

---

Résumé : Background: Pneumocystis pneumonia (PCP) case clusters involving solid organ transplant (SOT) recipients have been reported worldwide. Mycophenolic acid, an immunosuppressant used to prevent rejection in SOT recipients that targets the inosine 5 ′ -monophosphate dehydrogenase (IMPDH) protein, has been hypothesised to exert selective pressure on Pneumocystis jirovecii, with the missense mutation G1020A (Ala261Thr) in the impdh gene a possible marker of such selective pressure. The aim of this study was to test the hypothesis that SOT recipients harbour P jirovecii with mutations in the impdh gene and are infected with specific P jirovecii strains. Methods: In this retrospective, multicentre, cross-sectional study of nationally representative, individual-level data, we included SOT recipients, regardless of the organ transplanted, involved or not in a PCP case cluster, and non-SOT recipients (control group) without mycophenolic acid exposure, diagnosed with PCP from 26 French and one Swiss secondary health-care centres. We included patients aged 18 years or older for whom archival P jirovecii DNA extracts were available in sufficient quantity and quality. P jirovecii specimens were characterised using a multilocus sequence typing method including impdh gene analysis. The primary outcome of this study was the detection of the G1020A (Ala261Thr) mutation in the impdh gene. A multivariable logistic regression was done to assess the relation between this mutation and the following variables retrieved from medical records: age, mycophenolic acid exposure at the time of PCP diagnosis, involvement in a PCP case cluster, PCP prophylaxis, and clinical outcome. Findings: 58 SOT recipients (44 treated with mycophenolic acid) and 59 non-SOT recipients (control group; not treated with mycophenolic acid) diagnosed with PCP between Jan 1, 2001, and Dec 31, 2021, were enrolled. The G1020A (Ala261Thr) mutation was detected in P jirovecii specimens from 40 (68⋅9%) SOT recipients (37 treated with mycophenolic acid) and in none of the P jirovecii specimens from the patients in the control group. The multivariable analysis showed that the allele characterised by the G1020A mutation was associated with mycophenolic acid exposure at the time of PCP diagnosis (adjusted odds ratio 73⋅61 [95% CI 17⋅41-455⋅70]; p<0⋅0001) and involvement in a PCP case cluster (12⋅77 [1⋅58-171⋅90]; p=0⋅029), whereas it was not associated with age, PCP prophylaxis, and clinical deterioration. A second missense mutation, G1020T (Ala261Ser) was identified in P jirovecii specimens from three SOT recipients (two treated with mycophenolic acid). Two specific multilocus genotypes (MLG-31 and MLG-34) of P jirovecii associated with Ala261Thr and Ala261Ser substitutions in IMPDH, respectively, were detected only in SOT recipients (38 patients with MLG-31 and three patients with MLG-34). Interpretation SOT recipients in this study were primarily infected with specific P jirovecii strains with mutations in the impdh gene, which might confer a selective advantage as both the G1020A (Ala261Thr) and G1020T (Ala261Ser) are associated with mycophenolic acid resistance in other fungi. Mycophenolic acid selective pressure might explain the maintenance and circulation of these P jirovecii strains within this patient population, and consequently their potential involvement in PCP case clusters.

---

Fichiers liés : Hoffmann et al. Lancet Microbe, 2025.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/09/2025
• Auteurs : Mathieu OosterlakenAngelina RogliardoTatiana LipinaPierre-André LafonMireille Elodie TsitokanaMathilde KeckHéloïse CahuzacPierre Prieu-SerandonSéverine DiemCécile DerieuxCélia CamberlinChrystel LafontDamien F MeyerPatrick ChamesFranck VandermoerePhilippe MarinLaurent PrézeauDenis ServentAli SalahpourAmy J RamseyCarine BecamelJean-Philippe PinJulie KniazeffPhilippe Rondard
• Organismes : Institut de Génomique Fonctionnelle Institut de Génomique Fonctionnelle Institut des Neurosciences de Montpellier University of Toronto Institut de Génomique Fonctionnelle Institut de Génomique Fonctionnelle Service d'Ingénierie Moléculaire pour la Santé (ex SIMOPRO) Service d'Ingénierie Moléculaire pour la Santé (ex SIMOPRO) Institut de Génomique Fonctionnelle Institut de Génomique Fonctionnelle Institut de Génomique Fonctionnelle Institut de Génomique Fonctionnelle Institut de Génomique Fonctionnelle Centre de Recherche en Cancérologie de Marseille Centre de Recherche en Cancérologie de Marseille Institut de Génomique Fonctionnelle Centre de Recherche en Cancérologie de Marseille Institut de Génomique Fonctionnelle Institut de Génomique Fonctionnelle Service d'Ingénierie Moléculaire pour la Santé (ex SIMOPRO) University of Toronto University of Toronto Institut de Génomique Fonctionnelle Institut de Génomique Fonctionnelle Institut de Génomique Fonctionnelle Institut des Biomolécules Max Mousseron [Pôle Chimie Balard] Institut de Génomique Fonctionnelle
• Publié dans Nature le 29/10/2020

---

Résumé : There is an urgent need for efficient and innovative therapies to treat brain disorders such as psychiatric and neurodegenerative diseases. Immunotherapies have proved to be efficient in many medical areas, but have not been considered to treat brain diseases due to the poor brain penetration of immunoglobulins1,2. Here we developed a bivalent biparatopic antibody, made of two camelid heavy-chain antibodies (called nanobodies)3, one binding to, and the other potentiating the activity of, homodimeric metabotropic glutamate receptor 2. We show that this bivalent nanobody, given peripherally, reaches the brain and corrects cognitive deficits in two preclinical mouse models with endophenotypes resulting from NMDA receptor hypofunction. Notably, these in vivo effects last for at least 7 days after a single intraperitoneal injection and are maintained after subchronic treatment. Our results establish a proof of concept that nanobodies can target brain receptors, and pave the way for nanobody-based therapeutic strategies for the treatment of brain disorders.

---

Fichiers liés : Oosterlaken et al 2025.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/09/2025
• Auteurs : Patrick Moretto-CapelleAnthony ScemamaStéphane FaureEszter DudásPierre CafarelliJean-Philippe Champeaux
• Organismes : Interactions Ions-Matière (LCAR) Groupe THEO (LCPQ) Laboratoire Collisions Agrégats Réactivité Interactions Ions-Matière (LCAR) Interactions Ions-Matière (LCAR) Interactions Ions-Matière (LCAR)
• Publié dans Physical Chemistry Chemical Physics le 02/11/2020

---

Résumé :

---

Fichiers liés : Dicationic hydantoin HAL.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/09/2025
• Auteurs : Martin FaureLouis Le BivicMarouane BoukhrisAndrea CianciJean-David BlossierDounia MeddadLucie ChastaingtPhilippe LacroixJérôme JouanPierre-Marie PreuxNicole DarodesVictor AboyansJulien Magne
• Organismes : CHU Limoges Epidémiologie des Maladies Chroniques en zone tropicale Service de cardiologie [CHU Limoges] Service de cardiologie [CHU Limoges] Service de cardiologie [CHU Limoges] Service de cardiologie [CHU Limoges] Epidémiologie des Maladies Chroniques en zone tropicale Epidémiologie des Maladies Chroniques en zone tropicale Service de Chirurgie Thoracique et Vasculaire - Médecine vasculaire [CHU Limoges] Epidémiologie des Maladies Chroniques en zone tropicale Centre Hospitalier Universitaire Dupuytren 1 et 2 CHU Limoges Epidémiologie des Maladies Chroniques en zone tropicale Service de cardiologie [CHU Limoges] Epidémiologie des Maladies Chroniques en zone tropicale Service de cardiologie [CHU Limoges] Université de Limoges Epidémiologie des Maladies Chroniques en zone tropicale
• Publié dans Archives of cardiovascular diseases le 30/10/2020

---

Résumé : Background Due to common pathophysiology and shared risk factors, peripheral artery disease (PAD) is frequently present in patients with calcific aortic stenosis (AS). However, the prevalence of PAD in calcific AS and its prognostic impact require further investigation. Aims To describe the prevalence of PAD in patients with advanced AS requiring intervention and assess the impact of PAD on overall long-term mortality among patients undergoing transcatheter aortic valve replacement (TAVR). Methods All patients who underwent TAVR between 2014 and 2023 in our tertiary care centre were enrolled in a retrospective cohort. PAD was defined by the mention of a clinical diagnosis in medical records, significant arterial stenosis observed on the pre-procedural angio-computed tomography scan or a history of lower-limb revascularization. Results Among the 904 included patients (median [interquartile range] age 84.2 (79.9–87.4) years, 54.4% male), 212 (23.5%) had PAD. Patients with PAD had a significantly higher risk of mortality compared to patients without PAD (mean 5-year survival 40.0%, 95% confidence interval [CI] 32.2–49.6 vs. 52.7%, 95% CI 47.8–58.1; P = 0.008; adjusted hazard ratio [aHR] 1.31, 95% confidence interval [CI] 1.03–1.66; P = 0.029). Among patients without coronary artery disease (CAD), those with PAD alone had an increased risk of mortality (aHR 1.50, 95% CI 1.03–2.21; P = 0.037). Importantly, patients with PAD alone had significantly reduced survival compared to those with CAD alone (i.e. without PAD) (aHR 1.49, 95% CI 1.02-2.19; P = 0.040). However, the survival of patients with both PAD and CAD did not significantly differ from those with CAD without PAD. Conclusion PAD was independently associated with increased mortality in severe calcific AS. Importantly, this excess mortality among patients with PAD was not affected by the simultaneous presence of CAD. Similarly to patients with CAD, patients with AS and concomitant PAD should be considered at high risk of mortality.

---

Fichiers liés : Aortic stenosis.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/09/2025
• Auteurs : Pierre NahonClovis Lusivika-NzingaPhilippe MerleFabien ZoulimThomas DecaensNathalie Ganne-CarriéGeorges-Philippe PageauxVincent LeroyLaurent AlricJean-Pierre BronowickiMarc BourlièreJérôme GournayAlbert TranStanislas PolPhilippe MathurinVéronique Loustaud-RattiSophie MétivierVictor de LedinghenArmand AbergelDominique ThabutLouis d'AlterocheMohammed BouattourTarik AsselahDenis OuzanPaul CalesOlivier ChazouillèresMoana Gelu-SimeonDominique RoulotJérôme BoursierCarole CagnotSonia TamazirtAlina PascaleSamuel NilusmasMaïté LewinMarianne ZiolFabrice CarratJean-Charles Duclos-Vallée
• Organismes : Centre de Recherche des Cordeliers Institut Pierre Louis d'Epidémiologie et de Santé Publique Centre de Recherche en Cancérologie de Lyon Centre de Recherche en Cancérologie de Lyon Institute for Advanced Biosciences / Institut pour l'Avancée des Biosciences (Grenoble) Hôpital Avicenne [AP-HP] Centre de Recherche des Cordeliers Centre Hospitalier Régional Universitaire [Montpellier] Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB) Hôpital Henri Mondor Pharmacochimie et Biologie pour le Développement Nutrition-Génétique et Exposition aux Risques Environnementaux Service d'Hépato-gastro-entérologie [CHRU Nancy] Hôpital Saint-Joseph [Marseille] Institut des Maladies de l'Appareil Digestif Centre Hospitalier Régional Universitaire [CHU Lille] Université Côte d'Azur Hôpital Archet 2 [Nice] Centre méditerranéen de médecine moléculaire Service d'hépatologie médicale [CHU Cochin] Université Paris Descartes - Paris 5 Institute for Translational Research in Inflammation - U 1286 Biologie moléculaire et cellulaire des microorganismes Service de Bactériologie, Virologie, Hygiène [CHU Limoges] Centre Hospitalier Universitaire de Toulouse Centre Hospitalier Universitaire de Bordeaux Université de Bordeaux CHU Clermont-Ferrand CHU Pitié-Salpêtrière [AP-HP] Centre de recherche en épidémiologie et santé des populations Sorbonne Université Centre Hospitalier Régional Universitaire de Tours Hôpital Beaujon [AP-HP] Centre de recherche sur l'Inflammation Hôpital Beaujon [AP-HP] Centre de recherche sur l'Inflammation Institut Arnault Tzanck Hémodynamique, Interaction Fibrose et Invasivité tumorales Hépatiques Centre Hospitalier Universitaire d'Angers CHU Saint-Antoine [AP-HP] Institut de recherche en santé, environnement et travail CHU Pointe-à-Pitre / Abymes [Guadeloupe] Centre de Recherche des Cordeliers AP-HP - Hôpitaux Universitaires Paris Seine-Saint-Denis Hémodynamique, Interaction Fibrose et Invasivité tumorales Hépatiques Centre Hospitalier Universitaire d'Angers CHU de Grenoble-Alpes - Centre Hospitalier Universitaire CHU Grenoble ANRS - Maladies infectieuses émergentes Physiopathologie et traitement des maladies du foie Physiopathologie et traitement des maladies du foie Institut Pierre Louis d'Epidémiologie et de Santé Publique Centre Hépato-Biliaire [Hôpital Paul Brousse] Assistance publique - Hôpitaux de Paris (AP-HP) Centre de Recherche des Cordeliers Institut Pierre Louis d'Epidémiologie et de Santé Publique CHU Saint-Antoine [AP-HP] Centre hépato-biliaire Physiopathologie et traitement des maladies du foie
• Publié dans Journal of Hepatology le 23/10/2020

---

Résumé : Background & aims: Whether the dynamics of non-invasive tests (NITs) correlate with hepatocellular carcinoma (HCC) risk in patients with cirrhosis following sustained virological response (SVR) remains unknown. Thus, we aimed to describe NIT dynamics and assess their correlation with HCC risk. Methods: The dynamics of NITs (fibrosis-4 index [FIB-4], aspartate aminotransferase-to-platelet ratio index [APRI] and liver stiffness measurement) were described in patients with cirrhosis after SVR included in two prospective French multicenter cohorts (ANRS CO22 Hepather and CO12 CirVir) between 2006 and 2015. To assess their relationship with the risk of HCC, a joint modeling approach was employed using both standard and flexible models adjusted for age and sex. The impacts of NIT current value and slope during follow-up on HCC risk were assessed, considering competing risks of death. Results: A total of 3,067 patients with cirrhosis who achieved SVR were analyzed, among whom 228 (7.4%) developed HCC and 210 (6.9%) died during a 26-month follow-up. All NITs were increased at baseline in patients who ultimately developed HCC, whereas platelet counts were lower. All NITs improved in patients who did not develop HCC. More varied changes were observed during the follow-up of patients who ultimately developed HCC. Joint model analyses showed that current values of FIB-4, APRI and platelet count at any time impacted HCC risk. Only FIB-4 and APRI slopes influenced the same outcome. When considering NIT current value and slope simultaneously, only the current value of NITs impacted HCC risk while the slopes were not informative. Conclusions: The dynamics of NITs following SVR do not identify patients with cirrhosis who could be safely excluded from surveillance programs. NIT current value is more informative than slope, which will necessitate regularly re-assessment of HCC risk to design individualized surveillance strategies. Impact and implications: It has been postulated that monitoring non-invasive test (NIT) dynamics following HCV cure may provide information on the residual risk of hepatocellular carcinoma (HCC) in patients with cirrhosis and may allow for the discontinuation of surveillance in certain patient subsets. We analyzed data from over 3,000 patients and found that while all NITs improved in patients with cirrhosis who did not develop HCC, those who eventually developed liver cancer showed more varied changes in these tests. Specifically, the current values of tests like FIB-4 (fibrosis-4 index) and APRI (aspartate aminotransferase-to-platelet ratio index) were linked to an increased risk of HCC, while their slopes did not provide additional useful information, suggesting that dedicated prospective studies are warranted to define how repeated measurement of NITs could be combined with other variables into HCC risk stratification algorithms. Until then, HCC surveillance should be maintained in all patients with cirrhosis following HCV eradication, even in case of decreased NIT values.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/09/2025
• Auteurs : Nicolas BonfantiP. CholerJean-Christophe ClementPierre BarréFrançois BaudinLauric CecillonAmélie SaillardWilfried ThuillerJérôme PoulenardNorine KhedimRomain Goury
• Organismes : Environnements, Dynamiques et Territoires de Montagne Centre Alpin de Recherche sur les Réseaux Trophiques et Ecosystèmes Limniques Laboratoire d'Ecologie Alpine Centre Alpin de Recherche sur les Réseaux Trophiques et Ecosystèmes Limniques Laboratoire de géologie de l'ENS Institut des Sciences de la Terre de Paris Laboratoire de géologie de l'ENS Ambassade de France au Kénya Laboratoire d'Ecologie Alpine Laboratoire d'Ecologie Alpine Environnements, Dynamiques et Territoires de Montagne Environnements, Dynamiques et Territoires de Montagne Laboratoire d'Ecologie Alpine
• Publié dans Geoderma le 25/10/2020

---

Résumé : Estimating SOC stocks and stability, as well as modeling their response to rising temperatures, is crucial for predicting climate change impacts. This is particularly true in mountainous regions, where low temperatures slow down SOC decomposition, resulting in higher SOC stocks compared to soils at lower elevations. However, these stocks are also more vulnerable to warming, increasing the risk of SOC depletion. Such conditions create the potential for a positive feedback loop in which warming accelerates SOC losses, further amplifying climate change impacts on these sensitive ecosystems. To better understand the factors controlling SOC stocks and stability in mountain soils, we sampled 170 soil profiles along 29 elevation gradients in the western Alps from 280 to 3160 m a.s.l. We assessed SOC stocks and chemical composition using mid-infrared spectroscopy method and SOC stability with Rock-Eval® thermal analysis. Our findings, based on an unprecedented dataset, reveal a clear elevational pattern in SOC properties. SOC stocks increase with elevation up to the montane belt (1200–1500 m a.s.l.), remain relatively stable through the subalpine zone, and then decline beyond the subalpine/alpine boundary (2200–2400 m a.s.l.). Notably, this transition is also marked by a significant drop in SOC stability, suggesting a shift in the dominant stabilization processes at higher elevations. Our results also indicate that SOC stocks and stability are influenced by a complex interplay of factors. At higher elevations, climate emerges to be the dominant factor, whereas lithology and weathering play a more significant role at lower elevations. These results suggest that at high-elevations, harsh climatic conditions favor stabilization of SOC, while less developed soils limit organo-mineral interactions. In contrast, at warmer, lower elevations with higher carbon fluxes, more developed soils facilitate organo-mineral interactions, thereby enhancing SOC stability in the long term. Consequently, alpine grasslands, which contain substantial stocks of labile carbon stabilized by climatic conditions, appear to be particularly vulnerable to the effects of climate warming.

---

Fichiers liés : 1-s2.0-S0016706125002939-main.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 31/08/2025
• Auteurs : David Messika-ZeitounMichael W.A. ChuDenis BouchardThierry Le TourneauJulien TernaclePhilippe DemersLinrui GuoAngel Yi Nam FuJean Claude DibCharmaine LamThays SokolovAmedeo AnselmiDidier TchétchéOphélie Brault MeslinAnge GoutondjiYoan Lavie-BadiePatrick SeknadjiAugustin CoisneDimitri ArangalageAnne BernardUsha ManianMalek KassAntonio FioreArnaud MaudiereYohann BohbotAurélien SeemannNadjib HammoudiLoïc BièrePierre-Yves LerouxJessica ForcilloAntoine JeuBenjamin ElegamandjiChristine Selton-SutyMartine GilardClaire BouletiOmair ArshadJean-Francois LegareThiziri Si MoussiJian YeCatherine SportouchBindu BittiraLaura MunteFabrice BauerGéraldine OngAli Fatehi HassanabadJordan BernickGeorge WellsRoja GaudaBernard IungWilliam D.T. KentJean-François ObadiaJulien Dreyfus
• Organismes : University of Ottawa Heart Institute Western University [Ontario] Montreal Heart Institute - Institut de Cardiologie de Montréal Institut du Thorax [CHU Nantes] CHU de Bordeaux Pellegrin [Bordeaux] Montreal Heart Institute - Institut de Cardiologie de Montréal Western University [Ontario] University of Ottawa Heart Institute Clinique Ambroise Paré [Centres Médico-Chirurgicaux Ambroise Paré, Pierre Cherest, Hartmann] University of British Columbia [Canada] Hospices Civils de Lyon Centre Hospitalier Universitaire [Rennes] Laboratoire Traitement du Signal et de l'Image Clinique Pasteur [Toulouse] Institut Mutualiste de Montsouris Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand Centre Hospitalier Universitaire de Toulouse Hôpital Privé Jacques Cartier [Massy] Centre Hospitalier Régional Universitaire [CHU Lille] Laboratoire de Recherche Vasculaire Translationnelle Centre Hospitalier Régional Universitaire de Tours Membrane Signalling and Inflammation in reperfusion Injuries Hôpital Henri Mondor Hôpital Saint-Joseph [Marseille] Neurologie [CHU Amiens] Mécanismes physiopathologiques et conséquences des calcifications cardiovasculaires - UR UPJV 7517 Nouvelle Clinique de Tours Saint Gatien-Alliance [Tours] CHU Pitié-Salpêtrière [AP-HP] Centre Hospitalier Universitaire d'Angers Médipôle Lyon-Villeurbanne Université de Montréal Hôpital Privé Le Bois Ramsay Santé [Lille] Centre cardiologique du Nord Centre Hospitalier Universitaire de Nancy Hôpital Maison Blanche Centre hospitalier universitaire de Poitiers = Poitiers University Hospital Memorial University of Newfoundland = Université Memorial de Terre-Neuve [St. John's, Canada] Dalhousie University [Halifax] Centre hospitalier Félix-Guyon [Saint-Denis, La Réunion] St. Paul’s Hospital - University of British Columbia [Vancouver, BC, Canada] Clinique du Millénaire - Oc Santé [Montpellier] Health Sciences North Research Institute [Sudbury] Hôpital Européen Georges Pompidou [APHP] Hôpital Charles Nicolle [Rouen] University of Toronto University of Calgary University of Ottawa Heart Institute University of Ottawa Heart Institute University of Ottawa [Ottawa] AP-HP - Hôpital Bichat - Claude Bernard [Paris] Laboratoire de Recherche Vasculaire Translationnelle University of Calgary Hospices Civils de Lyon Centre cardiologique du Nord
• Publié dans Circulation le 29/10/2020

---

Résumé : Background: Comprehensive knowledge of the clinical presentation, contemporary management, and outcomes on "allcomer" patients referred for mitral valve surgery (MVS) are critical to evaluate current practice and adherence to guidelines, understand selection biases, and inform key stakeholders on quality improvement. Methods: MITRACURE is a large international retrospective registry of consecutive adult patients who underwent isolated or combined MVS for mitral regurgitation (MR) in France or Canada in 2019 with in-depth clinical and echocardiographic characterization. Patients operated on for isolated mitral stenosis or who had a prior mitral valve intervention were excluded. Data were obtained from detailed chart abstraction and were site reported. Results: In 2019, 3522 patients underwent MVS (48% combined) across 40 centers (88±46 MVSs/center, median 80, interquartile [51–131]). Mean age was 65±12 years, and 35% were women. The most common MR etiology was myxomatous (61%), followed by functional (9%), infective endocarditis (9%), and rheumatic disease (7%). MR quantification was performed in only 43%. Advanced clinical presentation was common: 43% were in New York Heart Association class III/IV, 30% exhibited congestive heart failure, 47% were on diuretics, 22% had atrial fibrillation/flutter, 35% presented with reduced ejection fraction, and 22% had pulmonary hypertension (≥50 mm Hg). Most patients were symptomatic or presented with class I/IIa indication for intervention, and an early intervention was performed only in 3% of patients. The repair rate was 62% overall and 80% in myxomatous disease. In-hospital mortality was 4.5% overall but 2.3% in patients with myxomatous MR (1.8% isolated, 3.1% combined). Conclusions: MITRACURE provides a contemporary, multicenter, "real-world" picture of the clinical presentation, management, and in-hospital outcomes of MVS for MR in two Western countries. Patients were often referred late in the disease process, with few patients undergoing early intervention. The higher mortality and lower repair rates reported may be more reflective of an unselected MR patient population but have room for improvement. Our results underline the need to develop strategies to improve management and outcomes of patients with MR.

---

Source